José Luis López Sendón

José Luis López Sendón

José Luis López Sendón
Position

Cardiologist at La Paz Hospital and researcher at IdiPAZ (Madrid)

Results are presented from the unsuccessful first clinical trial that aimed to reduce cardiovascular risk by lowering lipoprotein(a) levels

The HORIZON trial was the first to evaluate the potential effect on cardiovascular risk of a drug—pelacarsen—that reduces lipoprotein(a) levels in the blood. While this approach had generated high expectations, it did not prove successful in this trial, which involved 8,000 patients who had already experienced cardiovascular events. The negative results, which Novartis previewed in a press release in September, are being presented in full on November 7 at the American Heart Association congress and are published in NEJM.

0

Statins cause almost none of the side effects listed in their package inserts, according to a meta-analysis

Statins are a group of drugs widely used to lower cholesterol levels and reduce cardiovascular risk. Although they have been associated with various adverse effects, a meta-analysis of 19 clinical trials with more than 120,000 participants in total concludes that only four of the 66 side effects listed in the package inserts are caused by statins themselves and the risks are very low. The authors, who published their findings in The Lancet, recommend revising the current list of side effects on statin labels to better reflect the evidence so that patients and doctors can make clearer and more informed decisions about treatment.

0

Colchicine use reduces strokes and heart attacks in people with cardiovascular disease, according to a Cochrane review

A review conducted by the Cochrane Collaboration analyzed the effects of colchicine—a medication commonly used to treat some rheumatic diseases—on people who had already experienced a cardiovascular event. The review included 12 clinical trials with more than 23,000 patients and concluded that colchicine reduces the risk of stroke or heart attack in these individuals. Overall, for every 1,000 people treated, there were 9 fewer heart attacks and 8 fewer strokes compared to those who did not take the medication, with no apparent serious side effects.

0